{"id":"W4387047804","doi":"10.3390/curroncol30100633","title":"The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Nivolumab; Sorafenib; Hepatocellular carcinoma; Ipilimumab; Ramucirumab; Bevacizumab; Oncology; Regorafenib; Internal medicine; Durvalumab; Pembrolizumab; Lenvatinib; Cancer; Immunotherapy; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008922822,0.0004243301,0.0009493306,0.0005694097,0.00026018,0.00111194,0.0005035244,0.0007593124,0.004407595],"category_scores_gemma":[0.001130597,0.0001201649,0.0006257509,0.0004345619,0.000660829,0.002235285,0.0007774141,0.00333252,0.001540646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006832675,"about_ca_system_score_gemma":0.0007654568,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004392291,"about_ca_topic_score_gemma":0.001234507,"domain_scores_codex":[0.9996154,0.0001219865,0.00003064693,0.00007628628,0.0001133279,0.00004228199],"domain_scores_gemma":[0.9994351,0.0002009023,0.00007650534,0.00003558148,0.0001391799,0.000112707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006259152,0.00025821,0.001412386,0.003265785,0.0001442962,0.0005287658,0.0001394169,0.0007154546,0.005024389,0.01627304,0.05696752,0.9146448],"study_design_scores_gemma":[0.0002933212,0.001518072,0.003301254,0.001910678,0.0002267685,0.003591055,0.0001772444,0.001310642,0.002205352,0.01878552,0.9666104,0.00006964331],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.007156185,0.9395673,0.009207174,0.03078907,0.003658573,0.00004021762,0.0001546831,0.0001907086,0.009236192],"genre_scores_gemma":[0.0809414,0.8533565,0.01302692,0.03213276,0.01133814,0.0001298477,0.0005697873,0.0001096104,0.008395053],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004407595,"threshold_uncertainty_score":0.01474482,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4222211169854129,"score_gpt":0.4265163168720458,"score_spread":0.004295199886632906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}